Patents by Inventor Rinse KLOOSTER
Rinse KLOOSTER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240034794Abstract: The invention provides means and methods for inhibiting a biological activity of cells. In one embodiment the invention is concerned with a method of inhibiting a biological activity in a first or second cell mediated by the binding of two membrane proteins that are binding partners for each other. The mentioned biological activity is inhibited by providing the cells with an antibody or antibody like molecule that can bind to each of the mentioned binding partners and the binding blocks the binding of the two binding partners thereby inhibiting the mentioned biological activity.Type: ApplicationFiled: December 7, 2022Publication date: February 1, 2024Inventors: Cecilia Anna Wilhelmina GEUIJEN, Rinse KLOOSTER, Cornelis Adriaan DE KRUIF, Paulus Johannes TACKEN, Mark THROSBY, Ton LOGTENBERG
-
Publication number: 20230406932Abstract: The invention provides means and methods for interfering with Programmed Cell Death 1 protein (PD-1) and Lymphocyte activation 3 (LAG 3) mediated inhibition in a PD-1 and/or LAG3 positive cell. A method may comprise contacting said cell with an antibody or a functional part, derivative and/or analogue thereof that comprises a variable domain that can bind to an extracellular part of PD-1 and a variable domain that can bind to an extracellular part of LAG3, thereby inhibiting PD-1 and/or LAG3 mediated activity in said cell. The invention also provides antibodies or variants thereof that comprises a variable domain that can bind to an extracellular part of PD-1 and a variable domain that can bind to an extracellular part of LAG3.Type: ApplicationFiled: April 27, 2023Publication date: December 21, 2023Applicant: Merus N.V.Inventors: Cecilia Anna Wilhelmina GEUIJEN, Rinse KLOOSTER, Comelis Adriaan DE KRUIF, Paulus Johannes TACKEN, Mark THROSBY, Ton LOGTENBERG
-
Publication number: 20230357407Abstract: The disclosure provide means and methods for interfering with Programmed Cell Death 1 protein (PD-1) and T-cell immunoglobulin and mucin-domain containing-3 (TIM-3) mediated inhibition in a PD-1 and/or TIM-3 positive cell. A method may comprise contacting said cell with an antibody or a functional part, derivative and/or analogue thereof that comprises a variable domain that can bind to an extracellular part of PD-1 and a variable domain that can bind to an extracellular part of TIM-3, thereby inhibiting PD-1 and/or TIM-3 mediated activity in said cell. The invention also provides antibodies or variant thereof that comprises a variable domain that can bind to an extracellular part of PD-1 and a variable domain that can bind to an extracellular part of TIM-3.Type: ApplicationFiled: July 26, 2023Publication date: November 9, 2023Inventors: Cecilia Anna Wilhelmina GEUIJEN, Rinse KLOOSTER, Cornelis Adriaan DE KRUIF, Paulus Johannes TACKEN, Mark THROSBY, Ton LOGTENBERG
-
Patent number: 11753470Abstract: The disclosure provides means and methods for interfering with Programmed Cell Death 1 protein (PD-1) and T-cell immunoglobulin and mucin-domain containing-3 (TIM-3) mediated inhibition in a PD-1 and/or TIM-3 positive cell. A method may comprise contacting said cell with an antibody or a functional part, derivative and/or analogue thereof that comprises a variable domain that can bind to an extracellular part of PD-1 and a variable domain that can bind to an extracellular part of TIM-3, thereby inhibiting PD-1 and/or TIM-3 mediated activity in said cell. The invention also provides antibodies or variants thereof that comprises a variable domain that can bind to an extracellular part of PD-1 and a variable domain that can bind to an extracellular part of TIM-3.Type: GrantFiled: July 6, 2018Date of Patent: September 12, 2023Inventors: Cecilia Anna Wilhelmina Geuijen, Rinse Klooster, Cornelis Adriaan De Kruif, Paulus Johannes Tacken, Mark Throsby, Ton Logtenberg
-
Patent number: 11732043Abstract: The invention provides means and methods for interfering with Programmed Cell Death 1 protein (PD-1) and Lymphocyte activation 3 (LAG 3) mediated inhibition in a PD-1 and/or LAG3 positive cell. A method may comprise contacting said cell with an antibody or a functional part, derivative and/or analogue thereof that comprises a variable domain that can bind to an extracellular part of PD-1 and a variable domain that can bind to an extracellular part of LAG3, thereby inhibiting PD-1 and/or LAG3 mediated activity in said cell. The invention also provides antibodies or variants thereof that comprises a variable domain that can bind to an extracellular part of PD-1 and a variable domain that can bind to an extracellular part of LAG3.Type: GrantFiled: July 6, 2018Date of Patent: August 22, 2023Assignee: MERUS N.V.Inventors: Cecilia Anna Wilhelmina Geuijen, Rinse Klooster, Cornelis Adriaan De Kruif, Paulus Johannes Tacken, Mark Throsby, Ton Logtenberg
-
Publication number: 20230250190Abstract: The present disclosure relates to binding domains that bind cancer-associated MUC1, and binding moieties comprising such binding domains. The present disclosure further relates to the use of such binding domains or binding moieties in the treatment of cancer. The present disclosure also relates to nucleic acid encoding such binding domains or binding moieties, and a vector and cell comprising such nucleic acid.Type: ApplicationFiled: December 20, 2022Publication date: August 10, 2023Applicant: Merus N.V.Inventors: Rinse KLOOSTER, Ivy WIDJAJA, Patrick MAYES, Horacio G. NASTRI, Jing ZHOU, Vijay GUPTA, Bindu VARGHESE
-
Patent number: 11685786Abstract: The invention provides means and methods of stimulating activity of a member of the TNF receptor superfamily on a cell. The invention also provides binding molecules such as antibodies that comprises at least two antigen binding sites, wherein a first antigen binding site can bind an extracellular part of CD137 and a second antigen binding site can bind an extracellular part of PD-L1.Type: GrantFiled: September 22, 2017Date of Patent: June 27, 2023Assignee: MERUS N.V.Inventors: Cecilia Anna Wilhelmina Geuijen, Mark Throsby, Cornelis Adriaan De Kruif, Rinse Klooster, Paulus Johannes Tacken, Ton Logtenberg
-
Patent number: 11667714Abstract: The invention provides means and methods for inhibiting a biological activity of cells. In one embodiment the invention is concerned with a method of inhibiting a biological activity in a first or second cell mediated by the binding of two membrane proteins that are binding partners for each other. The mentioned biological activity is inhibited by providing the cells with an antibody or antibody like molecule that can bind to each of the mentioned binding partners and the binding blocks the binding of the two binding partners thereby inhibiting the mentioned biological activity.Type: GrantFiled: July 6, 2018Date of Patent: June 6, 2023Assignee: Merus N.V.Inventors: Cecilia Anna Wilhelmina Geuijen, Rinse Klooster, Cornelis Adriaan De Kruif, Paulus Johannes Tacken, Mark Throsby, Ton Logtenberg
-
Publication number: 20220281977Abstract: A PD-1/CD3 bispecific antibody or an antigen-binding fragment thereof useful for preventing, suppressing the progression of symptoms of or the recurrence of or treating autoimmune diseases is disclosed. The PD-1/CD3 bispecific antibody comprises a first arm specifically binding to PD-1 and a second arm specifically binding to CD3. The PD-1/CD3 bispecific antibody can be formulated into a formulation which can reduce the occurrence of adverse reactions called as infusion reaction or cytokine release syndrome and the bispecific antibody contributes to enhancement or duration of an effect of preventing, suppressing the progression of symptoms of or the recurrence of or treating autoimmune diseases.Type: ApplicationFiled: July 29, 2020Publication date: September 8, 2022Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Shiro SHIBAYAMA, Takuya SHIMBO, Tomoya TEZUKA, Mark THROSBY, Cornelis Adriaan DE KRUIF, Pieter Fokko VAN LOO, Rinse KLOOSTER
-
Publication number: 20220185885Abstract: An agent for preventing, suppressing the progression of symptoms of, suppressing the recurrence of or treating autoimmune diseases, comprising a bispecific antibody or an antibody fragment thereof, having a first arm specifically binding to PD-1 and a second arm specifically binding to CD19, as described herein.Type: ApplicationFiled: April 3, 2020Publication date: June 16, 2022Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Shiro SHIBAYAMA, Tomoya TEZUKA, Mark THROSBY, Cornelis Adriaan DE KRUIF, Pieter Fokko VAN LOO, Rinse KLOOSTER, Robertus Cornelis ROOVERS
-
Publication number: 20210332134Abstract: A bispecific antibody which is capable of specifically binding to PD-1 and CD3 is disclosed. The bispecific antibody is suitable for preventing, suppressing symptom progression or recurrence of, and/or treating autoimmune diseases. Also disclosed is a formulation which can reduce occurrence of adverse infusion reactions or adverse reaction called cytokine release syndrome. The bispecific antibody has the feature to allow interaction between PD-1 and PD-L1 as its ligand, contributes enhancement or duration of its effects.Type: ApplicationFiled: July 2, 2021Publication date: October 28, 2021Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Shiro SHIBAYAMA, Takuya SHIMBO, Tomoya TEZUKA, Mark THROSBY, Cornelis Adriaan de KRUIF, Pieter Fokko van LOO, Rinse KLOOSTER
-
Patent number: 11091550Abstract: A bispecific antibody which is capable of specifically binding to PD-1 and CD3 is disclosed. The bispecific antibody is suitable for preventing, suppressing symptom progression or recurrence of, and/or treating autoimmune diseases. Also disclosed is a formulation which can reduce occurrence of adverse infusion reactions or adverse reaction called cytokine release syndrome. The bispecific antibody has the feature to allow interaction between PD-1 and PD-L1 as its ligand, contributes enhancement or duration of its effects.Type: GrantFiled: February 8, 2019Date of Patent: August 17, 2021Assignee: ONO PHARMACEUTICAL CO., LTD.Inventors: Shiro Shibayama, Takuya Shimbo, Tomoya Tezuka, Mark Throsby, Cornelis Adriaan de Kruif, Pieter Fokko van Loo, Rinse Klooster
-
Publication number: 20210214441Abstract: A bispecific antibody which is capable of specifically binding to PD-1 and CD3 is disclosed. The bispecific antibody is suitable for preventing, suppressing symptom progression or recurrence of, and/or treating autoimmune diseases. Also disclosed is a formulation which can reduce occurrence of adverse infusion reactions or adverse reaction called cytokine release syndrome. The bispecific antibody has the feature to allow interaction between PD-1 and PD-L1 as its ligand, contributes enhancement or duration of its effects.Type: ApplicationFiled: February 8, 2019Publication date: July 15, 2021Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Shiro SHIBAYAMA, Takuya SHIMBO, Tomoya TEZUKA, Mark THROSBY, Cornelis Adriaan de KRUIF, Pieter Fokko van LOO, Rinse KLOOSTER
-
Publication number: 20200325227Abstract: The invention provides means and methods for inhibiting a biological activity of cells. In one embodiment the invention is concerned with a method of inhibiting a biological activity in a first or second cell mediated by the binding of two membrane proteins that are binding partners for each other. The mentioned biological activity is inhibited by providing the cells with an antibody or antibody like molecule that can bind to each of the mentioned binding partners and the binding blocks the binding of the two binding partners thereby inhibiting the mentioned biological activity.Type: ApplicationFiled: July 6, 2018Publication date: October 15, 2020Inventors: Cecilia Anna Wilhelmina GEUIJEN, Rinse KLOOSTER, Cornelis Adriaan DE KRUIF, Paulus Johannes TACKEN, Mark THROSBY, Ton LOGTENBERG
-
Publication number: 20200216540Abstract: The invention provides means and methods for interfering with Programmed Cell Death 1 protein (PD-1) and Lymphocyte activation 3 (LAG 3) mediated inhibition in a PD-1 and/or LAG3 positive cell. A method may comprise contacting said cell with an antibody or a functional part, derivative and/or analogue thereof that comprises a variable domain that can bind to an extracellular part of PD-1 and a variable domain that can bind to an extracellular part of LAG3, thereby inhibiting PD-1 and/or LAG3 mediated activity in said cell. The invention also provides antibodies or variants thereof that comprises a variable domain that can bind to an extracellular part of PD-1 and a variable domain that can bind to an extracellular part of LAG3.Type: ApplicationFiled: July 6, 2018Publication date: July 9, 2020Inventors: Cecilia Anna Wilhelmina GEUIJEN, Rinse KLOOSTER, Cornelis Adriaan DE KRUIF, Paulus Johannes TACKEN, Mark THROSBY, Ton LOGTENBERG
-
Publication number: 20200216539Abstract: The disclosure provides means and methods for interfering with Programmed Cell Death 1 protein (PD-1) and T-cell immunoglobulin and mucin-domain containing-3 (TIM-3) mediated inhibition in a PD-1 and/or TIM-3 positive cell. A method may comprise contacting said cell with an antibody or a functional part, derivative and/or analogue thereof that comprises a variable domain that can bind to an extracellular part of PD-1 and a variable domain that can bind to an extracellular part of TIM-3, thereby inhibiting PD-1 and/or TIM-3 mediated activity in said cell. The invention also provides antibodies or variants thereof that comprises a variable domain that can bind to an extracellular part of PD-1 and a variable domain that can bind to an extracellular part of TIM-3.Type: ApplicationFiled: July 6, 2018Publication date: July 9, 2020Inventors: Cecilia Anna Wilhelmina GEUIJEN, Rinse KLOOSTER, Cornelis Adriaan DE KRUIF, Paulus Johannes TACKEN, Mark THROSBY, Ton LOGTENBERG
-
Publication number: 20200017595Abstract: The invention provides means and methods of stimulating activity of a member of the TNF receptor superfamily on a cell. The invention also provides binding molecules such as antibodies that comprises at least two antigen binding sites, wherein a first antigen binding site can bind an extracellular part of said member and a second antigen binding site can bind an extracellular part of a second (different) membrane protein.Type: ApplicationFiled: September 22, 2017Publication date: January 16, 2020Inventors: Cecilia Anna Wilhelmina GEUIJEN, Mark THROSBY, Cornelis Adriaan DE KRUIF, Rinse KLOOSTER, Paulus Johannes TACKEN, Ton LOGTENBERG